



Press release

SHL to record additional revenues in 2016 from contract in Germany

Tel Aviv / Zurich, 17 May 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY), a leading provider and developer of advanced personal telemedicine solutions, announced today that it has generated an income of EUR 5.3 million from cost savings it delivered under a Chronic Disease Management Services contract in Germany, relating to the year 2015. This income will be recognized as revenue in the company's 2016 financial statements. It is not related to the adjustments announced in March 2016 related to some performance-based revenues associated with the service years 2013 to 2015, which reduced the related income receivable.

Yoav Rubinstein, acting CEO of SHL, said: “We are pleased with the results of the program. This continues to demonstrate the value delivered by SHL under Chronic Disease Management programs to our customers and their patients.”

For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, shl@irfcom.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.